Drug induced liver injury is associated with high mortality—A study from a tertiary care hospital in Pakistan
Open accessThe DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Abstract
BACKGROUND AND AIM: In light of few established drug induced liver injury (DILI) registries, this study aims to evaluate the clinical spectrum and predictors of mortality and morbidity of hospitalized patients with suspected DILI. PATIENTS AND METHODS: DILI cases were identified and categorized on basis of COIMS/RUCAM score and the exclusion of other liver diseases. Clinical and laboratory parameters were analyzed to identify the predictors of morbidity (prolonged hospital stay > 5 days) and mortality. RESULTS: Out of 462 patients, there were 264 (57.6%) males and the mean age of the cohort was 50.83 years (range: 20-94 years). DILI was classified as definite or highly probable in 31.1%, probable in 62.5%, and possible in 7.4% of cases. Pattern of liver injury was hepatocellular in 25.1%, cholestatic in 56.17%, and mixed in 18.72% of patients. Anti-tuberculosis drugs (ATDs) were found to be the most common category of drugs causing DILI, in 295 (63.9%) patients. Clinically, encephalopathy was present in 21.6% patients; other presenting symptoms included abdominal pain (57.1%), vomiting (57.1%), jaundice (54.1%) and pruritus (42.3%). In-hospital mortality was 26.5% and prolonged hospital stay (> 5 days) was observed in 35.93% of patients. Mortality was significantly greater in patients with encephalopathy, male gender, hepatocellular pattern of DILI, increased INR and use of ventilator support. CONCLUSION: In our study, the most frequent cause of DILI in hospitalized patients was ATDs. More than a quarter of patients died during hospital stay. A close control of clinical and biochemical parameters are required to prevent and monitor DILI, especially in patients taking ATDs in our region.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Overall, paracetamol accounted for a weighted mean of 55.7% (range 50.0-77.8%) of severe acute liver injury (ALI) and/or ALF [201-208] and 7.3% (range 1.2-29.2%) of drug-induced liver injury (DILI) [209-219] (see Figure 7).”
From Paracetamol (acetaminophen) overdose and hepatotoxicity: mechanism, treatment, prevention measures, and estimates of burden of disease (2023) · cites this paper as [215]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredIn the citing paper
“The country with the highest percentage of DILI cases caused by paracetamol was the U.S.A at almost 30% [217] followed by Pakistan at 16% [215].”
From Paracetamol (acetaminophen) overdose and hepatotoxicity: mechanism, treatment, prevention measures, and estimates of burden of disease (2023) · cites this paper as [215]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ostapowicz, G., Fontana, R. J., Schiødt, F. V., Larson, A., Davern, T. J., Han, S. H. B., McCashland, T. M., Shakil, A. O., Hay, J. E., Hynan, L., et al. (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-137-12-200212170-00007 · Cited by 2,227 · cited 3×
“In the United States, DILI accounts for nearly 10% of the total cases of acute hepatitis, 5% of all hospital admissions, and 50% of all cases of acute liver failures [5].”
BackgroundInfluentialDanan, G., & Benichou, C. (1993) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(93)90101-6 · Cited by 1,481
Features and outcomes of 899 patients with drug-induced liver injury: the DILIN Prospective Study
Chalasani, N., Bonkovsky, H. L., Fontana, R., Lee, W., Stolz, A., Talwalkar, J., Reddy, K. R., Watkins, P. B., Navarro, V., Barnhart, H., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.03.006 · Cited by 925 · cited 5×
“One important finding from this study is that the order and frequency of drugs associated with DILI is different from the list provided in the report from the Drug Induced Liver Injury Network (DILIN) and the Spanish Registry [13, 14].”
BackgroundResultInfluentialBjörnsson, E. S., Bergmann, O. M., Björnsson, H. K., Kvaran, R. B., & Olafsson, S. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.02.006 · Cited by 865 · cited 1×
“Other common drug groups include non-steroidal anti-inflammatory drugs (NSAIDs) [10, 14], herbal and dietary supplements (HDS) [15] and rarely statins [13, 16, 17].”
BackgroundACG Clinical Guideline: the diagnosis and management of idiosyncratic drug-induced liver injury
Chalasani, N. P., Hayashi, P. H., Bonkovsky, H. L., Navarro, V. J., Lee, W. M., & Fontana, R. J. (2014) · American Journal of Gastroenterology · doi:10.1038/ajg.2014.131 · Cited by 860
ANDRADE, R., LUCENA, M., FERNANDEZ, M., PELAEZ, G., PACHKORIA, K., GARCIARUIZ, E., GARCIAMUNOZ, B., GONZALEZGRANDE, R., PIZARRO, A., & DURAN, J. (2005) · Gastroenterology · doi:10.1016/j.gastro.2005.05.006 · Cited by 856 · cited 7×
“One important finding from this study is that the order and frequency of drugs associated with DILI is different from the list provided in the report from the Drug Induced Liver Injury Network (DILIN) and the Spanish Registry [13, 14].”
BackgroundResultInfluentialChalasani, N., Fontana, R. J., Bonkovsky, H. L., Watkins, P. B., Davern, T., Serrano, J., Yang, H., & Rochon, J. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.09.011 · Cited by 755
Incidence of drug-induced hepatic injuries: A French population-based study
Sgro, C., Clinard, F., Ouazir, K., Chanay, H., Allard, C., Guilleminet, C., Lenoir, C., Lemoine, A., & Hillon, P. (2002) · Hepatology · doi:10.1053/jhep.2002.34857 · Cited by 716
Drug-induced liver injury—types and phenotypes
Hoofnagle, J. H., & Björnsson, E. S. (2019) · New England Journal of Medicine · doi:10.1056/nejmra1816149 · Cited by 652
Outcome and prognostic markers in severe drug‐induced liver disease†
Björnsson, E., & Olsson, R. (2005) · Hepatology · doi:10.1002/hep.20800 · Cited by 524 · cited 1×
“The Spanish registry and a Swedish study have described the hepatocellular pattern of damage as the most common form of liver injury associated with high incidence of liver transplantation or death if patient with jaundice [14, 27].”
BackgroundDrug-induced liver injury: recent advances in diagnosis and risk assessment
Kullak-Ublick, G. A., Andrade, R. J., Merz, M., End, P., Benesic, A., Gerbes, A. L., & Aithal, G. P. (2017) · Gut · doi:10.1136/gutjnl-2016-313369 · Cited by 438 · cited 1×
“A third of patients treated with a protein kinase inhibitor experience liver injury, with pazopanib, sunitinib and regorafenib identified as the potentially lethal agents [18].”
BackgroundLiver injury from herbals and dietary supplements in the U.S. Drug-Induced Liver Injury Network
Navarro, V. J., Barnhart, H., Bonkovsky, H. L., Davern, T., Fontana, R. J., Grant, L., Reddy, R. K., Seeff, L. B., Serrano, J., Sherker, A. H., et al. (2014) · Hepatology · doi:10.1002/hep.27317 · Cited by 418
Upadhyay, A., Kumar, K., Kumar, A., & Mishra, H. (2010) · International Journal of Ayurveda Research · doi:10.4103/0974-7788.64405 · Cited by 366
Hepatotoxicity associated with statins: Reports of idiosyncratic liver injury post-marketing
Björnsson, E., Jacobsen, E. I., & Kalaitzakis, E. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2011.07.023 · Cited by 321 · cited 1×
“Other common drug groups include non-steroidal anti-inflammatory drugs (NSAIDs) [10, 14], herbal and dietary supplements (HDS) [15] and rarely statins [13, 16, 17].”
BackgroundCSH guidelines for the diagnosis and treatment of drug-induced liver injury
Drug-induced Liver Injury (DILI) Study Group, Yu, Y.-C., Chinese Society of Hepatology (CSH), Chinese Medical Association (CMA), Mao, Y.-M., Chen, C.-W., Chen, J.-J., Chen, J., Cong, W.-M., Ding, Y., et al. (2017) · Hepatology International · doi:10.1007/s12072-017-9793-2 · Cited by 254
Drug-Induced Hepatotoxicity: A Review
Pandit (2012) · Journal of Applied Pharmaceutical Science · doi:10.7324/japs.2012.2541 · Cited by 239 · cited 4×
“In the United States, DILI accounts for nearly 10% of the total cases of acute hepatitis, 5% of all hospital admissions, and 50% of all cases of acute liver failures [5].”
BackgroundInfluentialDevarbhavi, H., Dierkhising, R., Kremers, W. K., Sandeep, M. S., Karanth, D., & Adarsh, C. K. (2010) · American Journal of Gastroenterology · doi:10.1038/ajg.2010.287 · Cited by 195 · cited 1×
“Likewise in an Indian study, high-MELD score or a combination of ascites, encephalopathy, high bilirubin, prothrombin time, and leukocyte count were identified as predictors of mortality [28].”
BackgroundPorceddu, M., Buron, N., Roussel, C., Labbe, G., Fromenty, B., & Borgne-Sanchez, A. (2012) · Toxicological Sciences · doi:10.1093/toxsci/kfs197 · Cited by 181 · cited 1×
“Altogether, in excess of a thousand medicines and chemicals have been implicated in drug induced liver injury [3, 4].”
BackgroundPooled safety analysis of EGFR-TKI treatment for EGFR mutation-positive non-small cell lung cancer
Takeda, M., Okamoto, I., & Nakagawa, K. (2015) · Lung Cancer · doi:10.1016/j.lungcan.2015.01.026 · Cited by 178
Suzuki, A., Andrade, R. J., Bjornsson, E., Lucena, M. I., Lee, W. M., Yuen, N. A., Hunt, C. M., & Freston, J. W. (2010) · Drug Safety · doi:10.2165/11535340-000000000-00000 · Cited by 169 · cited 1×
“Conversely, the Spanish registry reported very low number of patients with fulminant hepatic failure with 11 out of 439 cases being classified as such [14, 25].”
BackgroundImportant Elements for the Diagnosis of Drug-Induced Liver Injury
Agarwal, V. K., McHutchison, J. G., & Hoofnagle, J. H. (2010) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2010.02.008 · Cited by 137
Almdal, T., & Sørensen, T. I. A. (1991) · PubMed · Cited by 130
Almdal, T. P., & Sørensen, T. I. A. (1991) · Hepatology · doi:10.1002/hep.1840130407 · Cited by 120 · cited 1×
“This likely reflects the differences in the epidemiology of infectious diseases and corresponded to numbers observed by other studies from this region [23].”
ResultDrug-Induced Hepatotoxicity: A Review
Pandit, A., Sachdeva, T., & Bafna, P. A. (2012) · Cited by 97
Jing, J., & Teschke, R. (2018) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2017.00033 · Cited by 89
Charles, E. C., Olson, K. L., Sandhoff, B. G., McClure, D. L., & Merenich, J. A. (2005) · The American Journal of Medicine · doi:10.1016/j.amjmed.2005.02.008 · Cited by 74
Rathi, C., Pipaliya, N., Patel, R., Ingle, M., Phadke, A., & Sawant, P. (2017) · Annals of Hepatology · doi:10.5604/01.3001.0009.8600 · Cited by 61
Evaluation of prognostic markers in severe drug-induced liver disease
Li, B. (2007) · World Journal of Gastroenterology · doi:10.3748/wjg.v13.i4.628 · Cited by 48 · cited 1×
“Additionally, the same study also identified that hepatic encephalopathy, ascites, jaundice, alcohol abuse and direct bilirubin levels were associated with the death of DILI patients [29].”
BackgroundEpidemiology and Genetic Risk Factors of Drug Hepatotoxicity
Ahmad, J., & Odin, J. A. (2017) · Clinics in Liver Disease · doi:10.1016/j.cld.2016.08.004 · Cited by 39 · cited 1×
“Causal association to a specific drug is not a straightforward matter, as it heavilydepends on exclusion of other causes (notably viral and autoimmune hepatitis) and temporal relationship of the drug to the derangement in patient’s liver function tests (LFTs) [7].”
BackgroundAscertainment of acute liver injury in two European primary care databases
Ruigómez, A., Brauer, R., Rodríguez, L. A. G., Huerta, C., Requena, G., Gil, M., de Abajo, F. J., Downey, G., Bate, A., Tepie, M. F., et al. (2014) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-014-1721-y · Cited by 35
Pang, L., Yang, W., & Hou, F.-Q. (2017) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2017.08.003 · Cited by 31 · cited 2×
“A recently published review found 9 of the top 10 causes of DILI to be antibiotics; this is a measure of their hepatotoxic potential, as well as the common use and duration of treatment with these drugs [20, 22].”
BackgroundDrug-Induced Liver Injury Is a Major Risk for New Drugs
Seeff, L. B. (2015) · Digestive Diseases · doi:10.1159/000374089 · Cited by 17 · cited 1×
“Specific laboratory criteria are utilized to identify DILI: generally, a 3–5 times elevation of liver enzymes, namely transaminases (alanine aminotransferase [ALT] or aspartate aminotransferase [AST]), alkaline phosphatase (ALP), or bilirubin, above their upper limit of normal (ULN) is required [2].”
MethodAlmdal, T. (1991) · Hepatology · doi:10.1016/0270-9139(91)92559-q · Cited by 16
Cited by
Chidiac, A. S., Buckley, N. A., Noghrehchi, F., & Cairns, R. (2023) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2023.2223959 · Cited by 215
Teschke, R., & Danan, G. (2020) · Medicines · doi:10.3390/medicines7100062 · Cited by 77
Drug‐Induced Liver Injury: Clinical Evidence of N‐Acetyl Cysteine Protective Effects
Ntamo, Y., Ziqubu, K., Chellan, N., Nkambule, B. B., Nyambuya, T. M., Mazibuko-Mbeje, S. E., Gabuza, K., Marcheggiani, F., Tiano, L., & Dludla, P. V. (2021) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2021/3320325 · Cited by 81
Bessone, F., García-Cortés, M., Medina-Caliz, I., Hernandez, N., Parana, R., Mendizabal, M., Schinoni, M. I., Ridruejo, E., Nunes, V., Peralta, M., et al. (2022) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2021.01.011 · Cited by 60
Mitochondrial Dynamics in Drug-Induced Liver Injury
Ramachandran, A., Umbaugh, D. S., & Jaeschke, H. (2021) · Livers · doi:10.3390/livers1030010 · Cited by 36
“DILI is associated with high mortality, especially in developing countries [2], and is a common cause for withdrawal of drugs from the market rendering it very important for pharmaceutical companies involved in drug development [3].”
Background
Metadata
- Authors
- Abid, A., Subhani, F., Kayani, F., Awan, S., & Abid, S.
- Affiliations
- Aga Khan University (PK)
- Corresponding author
- Abid, Shahab
- Venue
- PLOS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2020-04-10
- Volume
- 15
- Issue
- 4
- Pages
- e0231398
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC7148123
- OpenAlex
- W3016018703
- Cited by
- 22
- References
- 32
- Citations by year
- 2026: 1 · 2025: 6 · 2024: 2 · 2023: 4 · 2022: 3 · 2021: 3 · 2020: 3
- FWCI
- 2.87
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS ONE (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- eCommons - AKU (Aga Khan University) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Drug-Induced Hepatotoxicity and Protection
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Keywords
- drug-induced liver injury, mortality, antitubercular agents, hepatotoxicity, cholestatic liver injury, hepatocyte injury, encephalopathy, prolonged hospital stay, mortality risk factors, international normalized ratio, ventilator support, hospitalized patients
- MeSH terms
- Adult, Aged, Aged, 80 and over, Female, Humans, Length of Stay, Male, Middle Aged, Pakistan, Comorbidity, Chemical and Drug Induced Liver Injury, Tertiary Care Centers
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.